RA
PHVS icon

Rosalind Advisors’s Pharvaris PHVS Stock Holding History

Rosalind Advisors’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-223,627
Closed -$3.94M – 45
2025
Q2 		$3.94M Hold
223,627
– – 1.87% 20
2025
Q1 		$3.51M Buy
+223,627
New +$3.77M 1.71% 20

Other funds holding PHVS

GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Rosalind Advisors's PHVS Position: Q3 2025 in Review

Rosalind Advisors sold out of Pharvaris (PHVS) in Q3 2025, closing a stake of 223,627 shares — an estimated $3.94M sold.

Rosalind Advisors first reported a position in PHVS in Q1 2025 and held it in 2 quarters. The position peaked at $3.94M in Q2 2025. 83 funds tracked by Wall St. Rank hold PHVS as of Q3 2025.

  • Rosalind Advisors reported no remaining Pharvaris position as of Q3 2025 after selling out during the quarter.
  • Rosalind Advisors sold 223,627 Pharvaris shares in Q3 2025, an estimated $3.94M.
  • Rosalind Advisors first reported a position in Pharvaris in Q1 2025 and held it in 2 quarters.
  • Rosalind Advisors's Pharvaris position peaked at $3.94M in Q2 2025.
  • 83 funds tracked by Wall St. Rank held Pharvaris as of Q3 2025.

Based on Rosalind Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.